Current Editions
AI models will create whole new classes of therapies, by design
Discovery & Translation
Silent leadership, FDA cuts and lack of public trust are cracking biotech’s foundations — Editor’s Commentary
Editor's Commentary
The CCO role is evolving, argue John Archer and Roger Longman, as applicants must challenge entrenched views and manage a growing set of stakeholders with creativity
Guest Commentary
Public health groups, industry trying to counter flood of anti-vaccine messaging — including from Trump administration officials
Politics, Policy & Law
GOP appears willing to fix the ‘pill penalty,’ Trump is pushing for Medicaid most favored nation also
Politics, Policy & Law
VIB’s Jérôme van Biervliet says on The BioCentury Show that Europe needs to fulfill its long overdue mission in biotech as the U.S. enters uncertain terrain
Finance
Product Development
GSK’s Jemperli leads to sustained clinical complete responses in 95% of rectal cancer patients
Emerging Company Profile
Canadian start-up’s self-assembling scaffold creates high avidity antibodies against challenging targets
Guest Commentary
Political interference in product reviews threatens to undermine FDA’s credibility
Data Byte
A next-gen COVID vaccine among eight FDA decisions due in May
Regulation
The FDA commissioner says he’ll retain existing structure, which will require recruiting staff to fill critical positions
It isn’t clear whether staffing cuts or loss of FDA champions have caused FDA to miss the PDUFA goal for an ultrarare disease therapy
Politics, Policy & Law
FDA, HHS allow political appointees to make regulatory decisions about Novavax’s COVID vaccine based on unscientific rationales
New HHS vaccine policy could make it impossible to launch improved versions of vaccines
Deals
Structured deal could double the payout to Regulus’ shareholders if microRNA therapy, headed for Phase III testing in ADPKD, wins U.S. approval
German pharma adds drugs for rare tumors, expands U.S. footprint via $3.9B acquisition
Finance
Slow season continues for public offerings
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Management Tracks
BioCentury ISSN 1097-7201